Active substance
Results for the substance saxagliptin+dapagliflozin
1 result
About this active substance
Saxagliptin+dapagliflozin is a combination medication used in the treatment of type 2 diabetes mellitus. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of active incretins, stimulating insulin secretion and reducing glucagon production. Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that reduces renal glucose reabsorption, promoting its excretion through urine.
This combination is taken orally, usually once daily, and is indicated for patients who fail to control their blood sugar levels through diet, exercise, or other antidiabetic medications. It is effective in reducing glycated hemoglobin (HbA1c) levels and lowering cardiovascular risk.
Common side effects include urinary tract infections, genital infections, nausea, and headache. In rare cases, severe adverse reactions such as diabetic ketoacidosis or pancreatitis may occur. Regular monitoring of renal function and blood glucose levels is essential.
Saxagliptin+dapagliflozin is an innovative therapeutic option for patients with type 2 diabetes, offering multiple benefits through complementary mechanisms of action.
This combination is taken orally, usually once daily, and is indicated for patients who fail to control their blood sugar levels through diet, exercise, or other antidiabetic medications. It is effective in reducing glycated hemoglobin (HbA1c) levels and lowering cardiovascular risk.
Common side effects include urinary tract infections, genital infections, nausea, and headache. In rare cases, severe adverse reactions such as diabetic ketoacidosis or pancreatitis may occur. Regular monitoring of renal function and blood glucose levels is essential.
Saxagliptin+dapagliflozin is an innovative therapeutic option for patients with type 2 diabetes, offering multiple benefits through complementary mechanisms of action.